

SAPH2026

THE 19TH ANNUAL CONFERENCE OF
THE SAUDI ASSOCIATION FOR PULMONARY HYPERTENSION
12-14 FEBRUARY 2026 | HILTON HOTEL, JEDDAH, SAUDI ARABIA

ORGANIZED BY:



IN COLLABORATION WITH:



SCIENTIFIC PROGRAM

Dear Colleagues,

It gives me great pleasure to welcome you all to the 19th Annual Conference of the Saudi Association for Pulmonary Hypertension (**SAPH2026**) which will be held at Hilton Hotel, Jeddah, Saudi Arabia on **12-14 February 2026**.

SAPH is maintaining the quest for development and progress year after year. **SAPH2026** aims to create a platform for regional medical professionals to engage in exchange for knowledge and expertise on the latest and best practice methods in Pulmonary Hypertension.

As a Continuation of Successful Collaboration between the Saudi Association for Pulmonary Hypertension (**SAPH**) and the Pulmonary Vascular Research Institute (PVRI), it has been proven that it is highly successful and helped in introducing physicians in The Middle East and North African countries to the world experts in the field of Pulmonary Hypertension and to the most advanced developments in understanding and managing Pulmonary Hypertension.

The Scientific Committee is planning a comprehensive Scientific Program covering all aspects of Pulmonary Vascular Diseases in both Adult & Children, from the basics of Pathobiology and Pathophysiology, Diagnosis, Classification and Management to the most advanced development in Therapies and Interventional Modalities.

The program will be covered by the internationally recognized leaders in the field of Pulmonary Hypertension.

We are much appreciative to all our distinguished speakers and chairpersons. My hope is that all those who are practicing physicians will make an effort to attend and benefit from this Conference.

With my best regards,



Prof. Abdullah M. Aldalaan, MD

Chairman, the 19th Annual Conference of Saudi Association for Pulmonary Hypertension (SAPH2026)

Chairman, Saudi Association for Pulmonary Hypertension (SAPH)

Consultant, Pulmonary Medicine

Director, Pulmonary Hypertension Program, Lung Health Center

King Faisal Specialist Hospital & Research Centre

Professor of Medicine, Alfaisal University

Riyadh, Saudi Arabia



DAY 1 - THURSDAY

12 FEBRUARY 2026

EVENING SESSION

Pre-Conference Workshops

- 15:00 - 16:00

Comprehensive Multimodality Imaging Findings in PH/ CTEPH
Speaker:  Mnahi Bin Saeedan
Chair & Discussant:  Sarah K. Alrasheed
- 16:00 - 17:00

Right Heart Catheterization; State of the Art Measurements
Speaker:  Stephan Rosenkranz
Chair & Discussant:  Abdullah A. Al Masoud
- 17:00 - 18:00

Risk Stratification and Management; Case-Based Scenarios
Speaker:  Sean Gaine
Chair & Discussant:  Nawal A. Al Gubaisi

17:00 - 18:45 REGISTRATION

- 18:45 - 19:00

Welcome Notes
 Prof. Abdullah M. Aldalaan

Session 1: Keynote

- Chairs:

 Abdullah M. Alkhodair Saleh A. Aldammas
- 19:00 - 19:30

TGF-β Super family and PDGF Pathways Story: Origins, Breakthroughs, and Future Direction
 Paul Yu
- 19:30 - 20:00

PH: Year in Review, Key Milestones and Advances
 Husam M. Sakkijha
- 20:00 - 20:10

Q & A Panel Discussion

20:10 - 20:30 SAPH International Collaborating Societies Greetings

20:30 - 22:30 DINNER

END OF 1st DAY

DAY 2 - FRIDAY

13 FEBRUARY 2026

MORNING SESSION

07:30 - 08:15 REGISTRATION

Session 2: PAH Basic Science

- Chairs:

 Abdullah M. Aldalaan Mona Alotaibi
- 08:20 - 08:40

Unraveling the Genetic and Epigenetic Blueprint of PAH
 Soni Pullamessati
- 08:40 - 09:00

Deep Phenotyping; Endophenotypes-Based Ontology
  Mona Alotaibi
- 09:00 - 09:20

GDF2 Gene Mutation in High-Inbred Population with PAH
 Lama A. Alabdi
- 09:20 - 09:30

Q & A Panel Discussion

09:30 - 09:45 COFFEE BREAK

Session 3: PAH Management ; TGF-β Super Family Pathway

- Chairs:

 Stephan Rosenkranz Marc Humbert
- 09:45 - 10:05

Sotatercept in Newly Diagnosed PAH; Efficacy and Safety; (HYPERION Study)
 H. Ardeschir Ghofrani
- 10:05 - 10:25

Sotatercept Longterm Efficacy & Safety in PAH; SOTERIA Study
 Ioana Preston
- 10:25 - 10:45

Targeting the Activin Signaling Pathway in Cpc-PH due to HFpEF
 Jean Luc Vachery
- 10:45 - 11:00

Q & A Panel Discussion

11:00 - 13:30 PRAYER AND LUNCH BREAK

DAY 2 - FRIDAY

13 FEBRUARY 2026

AFTERNOON SESSION

Session 4: Pulmonary Arterial Hypertension Treatment (Miscellaneous)

Chairs:	 Hani Sabour	TBA
13:30 - 13:50	Exploring Novel Targets for the Next Generation of PAH Therapies  Anna R. Hemnes	
13:50 - 14:10	Targeting Smad 2/3 Signaling Pathway; A Potential Therapeutic Molecule with less side effect (ALG-801) 	
14:10 - 14:30	Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with PAH  Jean Luc Vachier	
14:30 - 14:50	Insights from PATH-GCC: PAH Treatment Patterns and Outcomes Across the Gulf Countries  Majdy M. Idrees	
14:50 - 15:00	Q & A Panel Discussion	

15:00 - 15:30 COFFEE BREAK

13:30 - 15:00 6 MINUTES WALKING TEST WORKSHOP

DAY 2 - FRIDAY

13 FEBRUARY 2026

AFTERNOON SESSION

Session 5: Challenging Real-life Cases

Chairs:	 Shaya Al Shaya	 Ragdah Arif	 Sean Gaine
15:30 - 15:50	PAH with Catastrophic Course with the Whole Spectrum of Intervention  Noura Alturaif		
15:50 - 16:10	A Rare Case of Subacute PAH  Fayez K. Al Ahmadi		
16:10 - 16:30	TBA TBA		
16:30 - 17:50	TBA TBA		

END OF 2nd DAY

DAY 3 - SATURDAY

14 FEBRUARY 2026

MORNING SESSION

Session 6: Pulmonary Hypertension Management (Focus on Group III)

Chairs:  Bader J. Alghamdi  Hassan Nuaimat

09:00 – 09:20 **PH Associated with CLD; RHC- Based timely Diagnosis and Role of Screening in PH-ILD**

 David Kiely

09:20 – 09:40 **PH- ILD; Contemporary Management**

 Luke Howard

09:40 – 10:00 **Inhaled Seralutinib in PH-ILD Treatment; a Potential Two Targets in One**

 Roham Zamanian

10:00 – 10:20 **PROSERA Trial; Patients Demographics**

 Olivier Sitbon

10:20 – 10:30 **Q & A Panel Discussion**

10:30 – 10:45 COFFEE BREAK

10:45 – 12:15 6 MINUTES WALKING TEST WORKSHOP

DAY 3 - SATURDAY

14 FEBRUARY 2026

MORNING SESSION

Session 7: CTEPH

Chairs:  Bader Alzahrani **TBA**

10:45 – 11:05 **Ten-year survival and prognostic factors after BPA in inoperable CTEPH**

 Hiromi Matsubara

11:05 – 11:25 **Optimizing BPA Outcomes: An Update on The Role of Medical Therapy Pre- and Post-Procedure**

 Irene Lang

11:25 – 11:45 **Automated detection of chronic thromboembolic disease on routine CT pulmonary Angiogram**

 David Kiely

11:45 – 12:10 **Balloon Pulmonary Angioplasty in Sickle Cell Disease with Chronic Thromboembolic Pulmonary Hypertension**

 Olivier Sitbon

12:10 – 12:20 **Q & A Panel Discussion**

12:20 – 12:30 CLOSING REMARKS

12:30 – 13:30 LUNCH

END OF 3st DAY

CONTACT:

Email: saphsts@gmail.com
+966 553 390 0404

© Saudi Association for Pulmonary Hypertension/ Saudi Thoracic Society, All Rights Reserved.